Trial Profile
Phase 2 Trial of Karenitecin (BNP1350) in Patients With Malignant Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 May 2021
Price :
$35
*
At a glance
- Drugs Cositecan (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors BioNumerik Pharmaceuticals
- 15 Aug 2014 New trial record